[ @entity308 tendency in @entity1 with XXXX ].

@entity1 @entity308 @entity134 @entity309 @entity214
OBJECTIVES: To determine if @entity308 scores are higher in @entity1 with @entity309 and to identify risk factors for @entity308 . METHOD: The subjects were 287 @entity309 in- @entity1 and outpatients. We investigated the tendency of @entity308 by @entity214 of Zung and whether @entity214 is correlated with age, face scale, VAS (visual analog scale), MHAQ, class, BSG and CRP. We compared the frequency of @entity308 tendency between those who took @entity134 and those who did not. Among 238 cases that we studied, 131 @entity1 took @entity134 hormone and the rest did not. RESULTS: It was found that 113 out of 287 @entity1 (about 39%) showed @entity308 tendency. @entity214 was correlated with face scale (r = 0.55198 P = 0.0001) followed by VAS (r = 0.40772 P = 0.0001). However, @entity214 was not correlated with BSG, CRP, age and duration range. For the group who took @entity134 hormone, the average score of @entity214 was 38.63 (+/- 8.37). The average score for the other group who did not take @entity134 was 35.98 (+/- 7.97). As a result, it was measured by T-value that the group who took @entity134 hormone had higher @entity214 than the other group who did not take @entity134 .
